In a report released today, Joseph Pantginis from H.C. Wainwright reiterated a Buy rating on aTyr Pharma (LIFE – Research Report), with a price target of $35.00.
Joseph Pantginis assigned a Buy rating to aTyr Pharma (LIFE) due to various factors, primarily related to the company’s robust financial health and promising clinical progress. The company’s third quarter financials were a key consideration, with aTyr reporting financial results that exceeded consensus estimates, with an EPS of ($0.20) compared to the predicted ($0.23). Additionally, aTyr’s cash reserve of $105.6 million was regarded as sufficient to sustain its operations until the submission of a BLA for efzofitimod in pulmonary sarcoidosis.
Moreover, Pantginis highlighted aTyr’s significant strides in advancing its primary candidate, efozofitimod, in two clinical studies for the treatment of interstitial lung disease (ILD). The Phase 3 EFZO-FIT study in patients with pulmonary sarcoidosis and the Phase 2 EFZO-CONNECT study in patients with systemic sclerosis (SSc-ILD) both showed encouraging updates and projected milestones. In particular, the positive DSMB review for the EFZO-FIT study, recommending its continuation without any modifications or additional safety measures, was seen as a major step forward. Pantginis also noted the ongoing enrollment in the EFZO-CONNECT study, with the first patient already dosed, as a significant development. The expansion of efzofitimod’s reach with these studies is perceived to bolster aTyr’s clinical development ambitions and to potentially enhance shareholder value.
According to TipRanks, Pantginis is an analyst with an average return of -14.2% and a 26.14% success rate. Pantginis covers the Healthcare sector, focusing on stocks such as PDS Biotechnology, Clene, and Ligand Pharma.
In another report released on October 31, JonesTrading also maintained a Buy rating on the stock with a $12.00 price target.
See the top stocks recommended by analysts >>
TipRanks tracks over 100,000 company insiders, identifying the select few who excel in timing their transactions. By upgrading to TipRanks Premium, you will gain access to this exclusive data and discover crucial insights to guide your investment decisions. Begin your TipRanks Premium journey today.
aTyr Pharma (LIFE) Company Description:
aTyr Pharma, Inc. develops protein therapeutics and novel class of biologic drugs. It plans to build a pipeline of therapeutic products based on Physiocrine biology. The company has established a dominant intellectual property estate to protect the core therapeutics as well as associated diagnostics. aTyr Pharma was founded by Paul Schimmel, Xiang-Lei Yang and Bruce Beutler on September 8, 2005 and is headquartered in San Diego, CA.
Read More on LIFE:
- aTyr Pharma to Present at November Investor Conferences
- aTyr Pharma announces dosing of first patient in Phase 2 EFZO-CONNECT study
- aTyr Pharma presents efzofitimod data
- aTyr Pharma Presents Efzofitimod Data Demonstrating Statistically Significant Improvements in Time to Relapse, FVC and Patient Reported Outcomes
